AMAG Pharmaceuticals Inc. (AMAG) Position Decreased by State Board of Administration of Florida Retirement System
State Board of Administration of Florida Retirement System reduced its position in shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) by 1.8% during the second quarter, Holdings Channel reports. The institutional investor owned 23,861 shares of the specialty pharmaceutical company’s stock after selling 446 shares during the period. State Board of Administration of Florida Retirement System owned about 0.07% of AMAG Pharmaceuticals worth $571,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in AMAG. BlackRock Inc. raised its position in shares of AMAG Pharmaceuticals by 528.5% in the first quarter. BlackRock Inc. now owns 4,299 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 3,615 shares during the period. Legal & General Group Plc raised its position in shares of AMAG Pharmaceuticals by 43.3% in the first quarter. Legal & General Group Plc now owns 9,492 shares of the specialty pharmaceutical company’s stock worth $221,000 after buying an additional 2,870 shares during the period. Societe Generale bought a new position in shares of AMAG Pharmaceuticals during the second quarter worth about $232,000. Bayesian Capital Management LP bought a new position in shares of AMAG Pharmaceuticals during the first quarter worth about $236,000. Finally, Capstone Asset Management Co. raised its position in shares of AMAG Pharmaceuticals by 5.1% in the second quarter. Capstone Asset Management Co. now owns 10,876 shares of the specialty pharmaceutical company’s stock worth $260,000 after buying an additional 530 shares during the period.
Shares of AMAG Pharmaceuticals Inc. (NASDAQ:AMAG) traded up 2.92% during midday trading on Wednesday, hitting $25.40. 146,488 shares of the stock traded hands. The company’s market capitalization is $867.51 million. The stock has a 50 day moving average of $24.39 and a 200 day moving average of $23.84. AMAG Pharmaceuticals Inc. has a 1-year low of $17.92 and a 1-year high of $42.49.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.20 by $0.25. AMAG Pharmaceuticals had a positive return on equity of 13.98% and a negative net margin of 4.87%. The business earned $127.40 million during the quarter, compared to the consensus estimate of $128.52 million. During the same quarter last year, the firm posted $1.12 EPS. The company’s quarterly revenue was up 46.7% on a year-over-year basis. Equities research analysts predict that AMAG Pharmaceuticals Inc. will post $5.43 earnings per share for the current fiscal year.
A number of brokerages recently issued reports on AMAG. Zacks Investment Research raised shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $26.00 target price on the stock in a research report on Friday, August 12th. Jefferies Group dropped their target price on shares of AMAG Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating on the stock in a research report on Wednesday, August 10th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. AMAG Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $36.78.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals Inc. (NASDAQ:AMAG).
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.